TRIMBOW (beclometasone / formoterol / glycopyrronium), combination of inhaled corticosteroid (ICS), long-acting beta-2-agonist (LABA) bronchodilator and long-acting muscarinic antagonist (LAMA) bronchodilator

Insufficient clinical benefit for the treatment of moderate COPD

• TRIMBOW, a fixed combination of beclometasone 87 µg/ formoterol 5 µg/ glycopyrronium 9 µg (ICS + LABA+ LAMA), has been granted a marketing authorisation for the long-term treatment of moderate to severe chronic obstructive pulmonary disease (COPD) in adults not treated satisfactorily with an ICS/LABA combination.

• It helps simplify treatment for patients with severe forms of the disease requiring inhaled triple therapy combining two long-acting bronchodilators (LABA + LAMA) and an ICS.

• TRIMBOW was statistically superior to a beclometasone/formoterol (ICS + LABA) combination in terms of FEV1, incidence of exacerbations and quality of life, but the differences were modest.